REVIEW ARTICLE

Year : 2012  |  Volume : 8  |  Issue : 4  |  Page : 510-519

Antimetabolites: Established cancer therapy

Manjul Tiwari
Department of Oral Pathology & Microbiology, School of Dental Sciences, Sharda University, India

Correspondence Address:
Manjul Tiwari
D-97, Anupam Apartments, B/13,Vasundhara Enclave, Delhi - 110096
India

Source of Support: None, Conflict of Interest: None

Check

13

DOI: 10.4103/0973-1482.106526

Cell death has been divided into two main types: programmed cell death, in which the cell plays an active role, and passive (necrotic) cell death. Senescence arrest, accelerated senescence and differentiation are also responses that can be induced in response to DNA-damaging agents. Apoptosis may occur as a primary event following chemotherapy, in which genes that regulate apoptosis will influence the outcome of therapy or, alternatively, as an event secondary to the induction of lethal damage that involves the subsequent processing of cellular damage. The particular type of response induced is highly dependent on the agent and dose employed, the type of DNA damage induced as well as the genetic and cellular phenotypes. It has been proposed that apoptosis may play a lesser role in tumor response to radiation in comparison with the induction of cell death through mitotic catastrophe or a senescence-like irreversible growth arrest. However, in comparison with the induction of apoptosis, there is a lack of as much definitive information on other cell death processes that occur in cancer cells in response to chemotherapeutic agents, including antimetabolites. This article reviews what is known about these processes at the present time in response to experimental or clinically used agents that are analogs of 5-fluorouracil, cytidine or purines, hydroxyurea, or that belong to the family of folate antagonists.

Keywords: Antimetabolites, apoptosis, cell death, mitotic catastrophe, necrosis

"The following article is been Retracted"

This article has been cited by 1 Iron Coordination Properties of Gramibactin as Model for the New Class of Diazeniumdiolate Based Siderophores Sofia Gama, Ron Hermenau, Mariachiara Frontauria, Demetrio Milea, Silvio Sammartano, Christian Hertweck, Winfried Plass Chemistry – A European Journal. 2021; 27(8): 2724 [Pubmed] | [DOI] 2 Design, Synthesis and Antitumoral Activity of New O -Alkylamidoximes Romário Jonas Oliveira, Cosme Silva Santos, Rodrigo Ribeiro Alves Caiana, Kleber Juvenal Silva Farias, Renato Ferreira Almeida Júnior, Paula Renata Lima Machado, Antônio Augusto Soares-Paulino, Paulo Henrique Menezes, Juliano Carlo Rufino Freitas ChemistrySelect. 2021; 6(33): 8774 [Pubmed] | [DOI] 3 Unboxing the molecular modalities of mutagens in cancer Smita Kumari, Sudhanshu Sharma, Dia Advani, Akanksha Khosla, Pravir Kumar, Rashmi K. Ambasta Environmental Science and Pollution Research. 2021; [Pubmed] | [DOI] 4 Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments Mohamed Yafout, Amine Ousaid, Youssef Khayati, Ibrahim Sbai El Otmani Scientific African. 2021; 11: e00685 [Pubmed] | [DOI] 5 Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals Siliang Jiang, Yu Fu, Xinyang Zhang, Tong Yu, Bowen Lu, Juan Du Frontiers in Bioengineering and Biotechnology. 2021; 9 [Pubmed] | [DOI] 6 Targeting the Metabolic Adaptation of Metastatic Cancer Josep Tarragó-Celada, Marta Cascante Cancers. 2021; 13(7): 1641 [Pubmed] | [DOI] 7 Hydroxyurea Induces Bone Marrow Mesenchymal Stromal Cells Senescence and Modifies Cell Functionality In Vitro Suncica Kapor, Milica Vukotic, Tijana Suboticki, Dragoslava Ðikic, Olivera Mitrovic Ajtic, Milica Radojkovic, Vladan P. Cokic, Juan F. Santibanez Journal of Personalized Medicine. 2021; 11(11): 1048 [Pubmed] | [DOI] 8 Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies O, A. Bezborodova, A. A. Pankratov, E. R. Nemtsova, Yu. B. Venediktova, M. S. Vorontsova, G. N. Engalycheva, R. D. Syubaev The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020; 10(2): 96 [Pubmed] | [DOI] 9 Editorial: Metabolism Meets Function: Untangling the Cross-Talk Between Signaling and Metabolism Alessandra Castegna, Daniel W. McVicar, Annalisa Campanella, Erika M. Palmieri, Alessio Menga, Paolo E. Porporato Frontiers in Oncology. 2020; 10 [Pubmed] | [DOI] 10 Ruthenium(II)–arene and triruthenium-carbonyl cluster complexes with new water-soluble phopsphites based on glucose: Synthesis, characterization and antiproliferative activity Maria R. Gonchar, Egor M. Matnurov, Tatiana A. Burdina, Oliver Zava, Tina Ridel, Elena R. Milaeva, Paul J. Dyson, Alexey A. Nazarov Journal of Organometallic Chemistry. 2020; 919: 121312 [Pubmed] | [DOI] 11 Inhibiting translesion DNA synthesis as an approach to combat drug resistance to DNA damaging agents Jung-Suk Choi, Seol Kim, Edward Motea, Anthony Berdis Oncotarget. 2017; 8(25): 40804 [Pubmed] | [DOI] 12 Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia Calum Leitch, Tereza Osdal, Vibeke Andresen, Maren Molland, Silje Kristiansen, Xuan Nhi Nguyen, Øystein Bruserud, Bjørn Tore Gjertsen, Emmet McCormack Oncotarget. 2016; 7(7): 8105 [Pubmed] | [DOI]